Table 2.
Symptom |
Whole group symptomatic |
No acetazolamide symptomatic |
Acetazolamide symptomatic |
P | |||
---|---|---|---|---|---|---|---|
No. | % | No. | % | No. | % | ||
Shortness of breath with activity | 213 | 87 | 125 | 89 | 84 | 91 | 0.61 |
Sleeping difficulty | 182 | 74 | 109 | 78 | 69 | 75 | 0.61 |
Headache | 162 | 66 | 99 | 71 | 61 | 66 | 0.48 |
Fatigue | 160 | 65 | 94 | 67 | 64 | 70 | 0.70 |
Dizzy/lightheaded | 113 | 46 | 68 | 49 | 43 | 47 | 0.78 |
General health limitation | 99 | 41 | 53 | 38 | 44 | 48 | 0.13 |
Mental status changes | 90 | 37 | 48 | 34 | 41 | 45 | 0.12 |
Shortness of breath at rest | 77 | 31 | 43 | 31 | 32 | 35 | 0.52 |
Cough | 74 | 30 | 34 | 24 | 37 | 41 | 0.008 |
GI upset | 59 | 24 | 26 | 19 | 31 | 34 | 0.009 |
Peripheral edema | 23 | 9 | 17 | 12 | 6 | 7 | 0.16 |
AMS by Lake Louise criteria | 116 | 52 | 70 | 52 | 46 | 51 | 0.87 |